Suppliers and packagers for generic pharmaceutical drug: BENDAMUSTINE HYDROCHLORIDE

BENDAMUSTINE HYDROCHLORIDE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Accord Hlthcare	BENDAMUSTINE HYDROCHLORIDE	bendamustine hydrochloride	POWDER;INTRAVENOUS	205574	ANDA	Accord Healthcare, Inc.	16729-250-03	1 VIAL, SINGLE-DOSE in 1 CARTON (16729-250-03) / 5 mL in 1 VIAL, SINGLE-DOSE	2022-12-07
Accord Hlthcare	BENDAMUSTINE HYDROCHLORIDE	bendamustine hydrochloride	POWDER;INTRAVENOUS	205574	ANDA	Accord Healthcare, Inc.	16729-251-05	1 VIAL, SINGLE-DOSE in 1 CARTON (16729-251-05) / 20 mL in 1 VIAL, SINGLE-DOSE	2022-12-07
Accord Hlthcare	BENDAMUSTINE HYDROCHLORIDE	bendamustine hydrochloride	POWDER;INTRAVENOUS	205574	ANDA	BluePoint Laboratories	68001-572-41	1 VIAL, SINGLE-DOSE in 1 CARTON (68001-572-41) / 20 mL in 1 VIAL, SINGLE-DOSE	2023-09-15

Bendamustine Hydrochloride Suppliers: Global Market Analysis

Last updated: February 19, 2026

This report identifies key suppliers of Bendamustine Hydrochloride, analyzes their manufacturing capabilities, and assesses market dynamics for this oncology drug. The market for Bendamustine Hydrochloride is characterized by established active pharmaceutical ingredient (API) manufacturers and emerging players, driven by demand in hematological malignancies.

What is Bendamustine Hydrochloride?

Bendamustine Hydrochloride is an alkylating agent with antineoplastic activity used in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL). Its mechanism of action involves DNA damage, leading to cell death. The compound is chemically designated as 4-{5-[Bis(2-chloroethyl)amino]-1-methyl-1H-benzimidazol-2-yl}butanoic acid hydrochloride.

Key Active Pharmaceutical Ingredient (API) Manufacturers

Several pharmaceutical ingredient manufacturers globally produce Bendamustine Hydrochloride API. These suppliers range from large, diversified chemical companies to specialized API producers.

Primary API Suppliers:

• Celanese Corporation (US/Germany): While Celanese is a broad chemical company, its subsidiary, Clariant, has historically been involved in complex pharmaceutical intermediates. Specific public information on Celanese's current direct Bendamustine HCl API manufacturing is limited but its chemical synthesis capabilities are relevant.
• Jubilant Pharmova Limited (India): Jubilant is a significant player in the global pharmaceutical ingredients market, with established expertise in complex API manufacturing. They supply a range of oncology APIs.
• Hikma Pharmaceuticals PLC (UK/Jordan): Hikma is a global pharmaceutical company with a strong presence in generic injectables and APIs. They are known to produce Bendamustine HCl API for both their own finished dosage forms and for other pharmaceutical companies.
• Eisai Co., Ltd. (Japan): Eisai, the originator of Bendamustine (under the brand name Treanda, Ribomustin, Levact), has in-house API manufacturing capabilities and also works with contract manufacturing organizations (CMOs).
• Sun Pharmaceutical Industries Ltd. (India): As one of the largest generic pharmaceutical companies globally, Sun Pharma has extensive API manufacturing facilities and a broad portfolio, including oncology drugs.
• Baxter International Inc. (US): While primarily known for finished dosage forms, Baxter has integrated supply chains and API sourcing for its key products, which include Bendamustine Hydrochloride injectables.
• Fresenius Kabi AG (Germany): Similar to Baxter, Fresenius Kabi is a major producer of injectable drugs and manages its supply chain, including API sourcing, for products like Bendamustine.
• Nantong Aurora Pharmaceutical Co., Ltd. (China): A specialized API manufacturer, Nantong Aurora is involved in the production of various oncology APIs, including Bendamustine Hydrochloride, serving global markets.
• Qingdao Eon Pharmaceutical Co., Ltd. (China): Another Chinese API supplier with capabilities in complex organic synthesis for pharmaceutical ingredients.

Manufacturing and Quality Standards

Suppliers of Bendamustine Hydrochloride API must adhere to stringent regulatory requirements. This includes:

• Good Manufacturing Practices (GMP): Compliance with GMP standards set by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other national health authorities is mandatory.
• Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory agencies to provide detailed information about their manufacturing process, quality controls, and facility. These are referenced by pharmaceutical companies seeking approval for their finished drug products.
• Impurity Profiling: Comprehensive analysis and control of impurities, including process-related impurities and degradants, are critical for patient safety and regulatory compliance. Bendamustine is known for its potential for degradation products, requiring robust stability studies.
• Chiral Purity: While Bendamustine Hydrochloride is not a chiral molecule, the precise control of chemical synthesis is vital to ensure the correct isomer and prevent unintended byproducts.

Market Dynamics and Demand Drivers

The demand for Bendamustine Hydrochloride is primarily driven by its established use in treating specific hematological cancers:

• Chronic Lymphocytic Leukemia (CLL): Bendamustine, often in combination regimens, is a standard treatment option for CLL, particularly for patients who have progressed after initial therapy.
• Indolent B-cell Non-Hodgkin Lymphoma (NHL): It is also approved for the treatment of indolent B-cell NHL in patients who have not responded to or have progressed during rituximab-containing therapy.

The market is influenced by:

• Generic Competition: Following patent expiries of originator products, generic versions of Bendamustine Hydrochloride have entered the market, increasing accessibility and driving down prices. This has led to increased demand for API from multiple generic manufacturers.
• Oncology Drug Development: Ongoing research into new cancer therapies may introduce alternative treatments, but Bendamustine's established efficacy in its approved indications ensures continued demand.
• Regulatory Approvals: Expansion of indications or approval in new geographic markets can further boost demand.
• Supply Chain Reliability: Pharmaceutical companies prioritize suppliers with a proven track record of quality, consistency, and robust supply chain management.

Global Supply Chain Considerations

The global supply chain for Bendamustine Hydrochloride API is concentrated in regions with strong chemical and pharmaceutical manufacturing bases.

Key Geographic Regions for API Production:

• India: A major hub for generic API manufacturing, offering competitive pricing and large-scale production capabilities.
• China: Another significant source of pharmaceutical ingredients, known for its extensive chemical synthesis infrastructure.
• Europe (Germany, UK): Home to established pharmaceutical companies and specialized API manufacturers, often focusing on high-quality, regulated production.
• United States: Hosts API manufacturing for key innovator drugs and some specialized generics.

Supply Chain Risks:

• Geopolitical Instability: Disruptions in manufacturing or transportation due to political events or trade disputes.
• Regulatory Scrutiny: Increased inspections and enforcement actions by regulatory bodies can impact production capacity and lead times.
• Raw Material Sourcing: Dependence on specific raw material suppliers can create vulnerabilities.
• Quality Control Failures: Any lapse in quality control can lead to product recalls, regulatory sanctions, and significant reputational damage.

Key Takeaways

The Bendamustine Hydrochloride API market is robust, supported by its established therapeutic role in hematological malignancies. Key suppliers, primarily located in India, China, and Europe, must meet stringent GMP and regulatory requirements. The market is characterized by generic competition, driving demand for cost-effective and high-quality API. Pharmaceutical companies making R&D or investment decisions should focus on suppliers with demonstrated quality compliance, robust supply chain management, and a commitment to regulatory standards.

Frequently Asked Questions

What are the primary therapeutic indications for Bendamustine Hydrochloride?

Bendamustine Hydrochloride is primarily indicated for the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) in adult patients who have not responded to or have progressed during prior therapy.

Which countries are major manufacturing hubs for Bendamustine Hydrochloride API?

Major manufacturing hubs for Bendamustine Hydrochloride API include India, China, and European countries such as Germany and the United Kingdom.

What regulatory standards must Bendamustine Hydrochloride API suppliers meet?

Suppliers must adhere to Good Manufacturing Practices (GMP) as defined by regulatory agencies like the FDA and EMA, and typically file Drug Master Files (DMFs) for their products.

How has patent expiry impacted the Bendamustine Hydrochloride market?

Patent expiry has led to increased generic competition, making Bendamustine Hydrochloride more accessible and driving demand for API from multiple generic manufacturers.

What are the key risks associated with the Bendamustine Hydrochloride supply chain?

Key risks include geopolitical instability, increased regulatory scrutiny, reliance on specific raw material suppliers, and potential quality control failures.

List of Cited Sources

[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from [FDA Website] (Note: Actual URL would be specific to the FDA DMF guidance page, which changes. This is a placeholder for the concept.) [2] European Medicines Agency. (n.d.). Good Manufacturing Practice (GMP). Retrieved from [EMA Website] (Note: Actual URL would be specific to the EMA GMP guidance page.) [3] Jubilant Pharmova Limited. (n.d.). Active Pharmaceutical Ingredients. Retrieved from Jubilant Pharmova Official Website. [4] Hikma Pharmaceuticals PLC. (n.d.). APIs. Retrieved from Hikma Pharmaceuticals Official Website. [5] Sun Pharmaceutical Industries Ltd. (n.d.). API Manufacturing. Retrieved from Sun Pharma Official Website. [6] Nantong Aurora Pharmaceutical Co., Ltd. (n.d.). Product List. Retrieved from Nantong Aurora Official Website.